Filtros de búsqueda

Lista de obras de

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

artículo científico publicado en 2015

A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults.

artículo científico publicado en 2017

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis

artículo científico publicado en 2019

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis

artículo científico publicado en 2018

A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.

artículo científico publicado en 2017

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia

artículo científico publicado en 2017

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.

artículo científico publicado en 2017

A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia

artículo científico publicado en 2014

A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase

artículo científico publicado en 2016

A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2017

Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia

artículo científico publicado en 2012

Acute myeloid leukemia: advancing clinical trials and promising therapeutics

artículo científico publicado en 2016

Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia

artículo científico publicado en 2018

Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study

artículo científico publicado en 2013

Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy

artículo científico publicado en 2014

Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia

artículo científico publicado en 2020

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).

artículo científico publicado en 2014

Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia

artículo científico publicado en 2013

Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome

artículo científico publicado en 2015

Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias

scientific article published on 27 September 2016

CD123 expression patterns and selective targeting with a CD123-specific antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia

scholarly article by Evgeniya Angelova et al published 25 October 2018 in Haematologica

Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia

artículo científico publicado en 2014

Characteristics of Sweet Syndrome in patients with acute myeloid leukemia

artículo científico publicado en 2014

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

artículo científico publicado en 2017

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial

scientific article published on 13 August 2018

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia

artículo científico publicado en 2018

Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid Malignancies

artículo científico publicado en 2017

Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia

artículo científico publicado en 2020

Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience

artículo científico

Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction

artículo científico publicado en 2015

Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations

scientific article published on 29 October 2020

Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis

artículo científico publicado en 2014

Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

artículo científico publicado en 2017

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

artículo científico publicado en 2016

Clinical significance of microcytosis in patients with primary myelofibrosis

artículo científico publicado en 2014

Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study

artículo científico publicado en 2016

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia

artículo científico publicado en 2013

Clonal Evolution and Treatment Outcomes in Hematopoietic Neoplasms Arising in Patients with Germline RUNX1 mutations

scientific article published on 17 August 2020

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation

artículo científico publicado en 2017

Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients

artículo científico publicado en 2017

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

artículo científico publicado en 2015

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

scientific article published on 01 December 2018

Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

artículo científico publicado en 2015

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes

artículo científico publicado en 2015

Dorsal column myelopathy after intrathecal chemotherapy for leukemia

artículo científico publicado en 2016

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.

artículo científico publicado en 2017

Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy

artículo científico publicado en 2013

Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL

scientific article published on 01 May 2019

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study

artículo científico publicado en 2018

Epidemiology of neurocysticercosis in Houston, Texas.

artículo científico publicado en 2005

Epstein-Barr virus-induced CD30-positive diffuse large B-cell lymphoma in a patient with mixed-phenotypic leukemia treated with clofarabine

artículo científico publicado en 2012

Extramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B-LBL): a diagnostic challenge

artículo científico publicado en 2014

Extramedullary acute myeloid leukemia: leukemic pleural effusion, case report and review of the literature

artículo científico publicado en 2014

FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia

artículo científico publicado en 2012

Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications

artículo científico publicado en 2015

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

artículo científico publicado en 2015

Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

artículo científico publicado en 2018

Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen

artículo científico publicado en 2016

Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis

artículo científico publicado en 2016

Frontline treatment of acute myeloid leukemia in adults

artículo científico publicado en 2016

Genetic Biomarkers Of Sensitivity and Resistance to Venetoclax Monotherapy in Patients With Relapsed Acute Myeloid Leukemia

scientific article published on 17 May 2018

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

artículo científico publicado en 2020

Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

artículo científico publicado en 2017

Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation

artículo científico publicado en 2019

Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance

artículo científico publicado en 2017

Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.

artículo científico publicado en 2017

Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma

artículo científico publicado en 2017

Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis

artículo científico publicado en 2016

Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial

artículo científico publicado en 2020

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

artículo científico publicado en 2019

Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors

artículo científico publicado en 2017

Immunotherapy based approaches in myelofibrosis

artículo científico

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

artículo científico publicado en 2016

Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin

scientific article published on 30 April 2020

Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

artículo científico publicado en 2017

Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes

artículo científico publicado en 2014

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.

artículo científico publicado en 2018

Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade

artículo científico publicado en 2015

Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors

artículo científico publicado en 2019

Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide

artículo científico publicado en 2014

Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphobl

scientific article published on 15 April 2019

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

artículo científico publicado en 2018

Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts

scientific article published on 29 April 2019

Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?

scientific article published on 01 February 2020

Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting

artículo científico publicado en 2017

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab

artículo científico publicado en 2016

Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes

artículo científico publicado en 2016

Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia

artículo científico publicado en 2017

Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation

scientific article published on 11 July 2019

Modest activity of pomalidomide in patients with myelofibrosis and significant anemia

artículo científico publicado en 2013

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

artículo científico publicado en 2017

Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse

artículo científico publicado en 2013

Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable

artículo científico publicado en 2018

Myeloid/lymphoid neoplasms with FGFR1 rearrangement

artículo científico publicado en 2017

Myelopathy following intrathecal chemotherapy in adults: a single institution experience

artículo científico publicado en 2015

Natural History of Newly Diagnosed Myelodysplastic Syndrome with Isolated Inv(3)/t(3;3)

artículo científico publicado en 2020

New directions for emerging therapies in acute myeloid leukemia: the next chapter

artículo científico publicado en 2020

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia

artículo científico publicado en 2019

Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia

artículo científico publicado en 2016

Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium

artículo científico publicado en 2014

Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression

artículo científico publicado en 2017

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

scientific article published on 28 February 2020

Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy

artículo científico publicado en 2019

Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure

artículo científico publicado en 2014

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia

artículo científico publicado en 2018

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

scientific article published on 08 October 2020

P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival

scientific article published on 23 September 2018

Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis

artículo científico publicado en 2017

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

artículo científico publicado en 2016

Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients

artículo científico publicado en 2020

Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies

artículo científico publicado en 2012

Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia

scientific article published on 22 January 2019

Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

artículo científico publicado en 2020

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

artículo científico publicado en 2013

Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents

artículo científico publicado en 2016

Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia

artículo científico publicado en 2020

Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

artículo científico publicado en 2015

Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

artículo científico publicado en 2015

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia

scientific article published on 20 December 2018

Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia

artículo científico publicado en 2014

Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia

artículo científico publicado en 2014

Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

artículo científico publicado en 2020

Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study

artículo científico publicado en 2015

Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor

artículo científico publicado en 2016

Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors

scientific article published on 03 March 2020

Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase

artículo científico publicado en 2017

Primary gastric chorioadenocarcinoma: a needle in a haystack

artículo científico publicado en 2011

Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients

artículo científico publicado en 2017

Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia

artículo científico publicado en 2016

Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease

artículo científico publicado en 2016

Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics

artículo científico publicado en 2014

Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors

artículo científico publicado en 2017

Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib

artículo científico publicado en 2019

Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia

artículo científico publicado en 2015

Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era

artículo científico publicado en 2020

Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation

artículo científico publicado en 2017

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

artículo científico publicado en 2015

Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.

artículo científico publicado en 2018

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

scientific article published on 18 June 2015

Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia

artículo científico publicado en 2017

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

artículo científico publicado en 2015

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study

scientific article published on 22 December 2014

Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis

artículo científico publicado en 2017

Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia

scientific article published on 31 August 2018

Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia

scientific article published on 16 July 2019

Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature

artículo científico publicado en 2015

Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years

artículo científico publicado en 2020

Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations

artículo científico publicado en 2015

TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes

artículo científico publicado en 2016

The LEukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase: A Model to Improve Patient Outcomes

artículo científico publicado en 2020

The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

artículo científico publicado en 2018

The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes

artículo científico publicado en 2014

The emerging role of immune checkpoint based approaches in AML and MDS.

artículo científico publicado en 2017

The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia

artículo científico publicado en 2012

The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia.

artículo científico publicado en 2016

Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase

artículo científico publicado en 2015

Time to response and survival in hypomethylating agent-treated acute myeloid leukemia

artículo científico publicado en 2017

Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.

artículo científico publicado en 2018

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis

artículo científico publicado en 2017

Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options

artículo científico publicado en 2012

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

scientific article published on 10 December 2018

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

scholarly article by Kamal Chamoun et al published 3 January 2019 in Journal of Hematology & Oncology

Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia

scientific article published on 31 May 2019

Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes

scientific article published on 06 December 2018

Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality

scientific article published on 02 December 2020

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

artículo científico publicado en 2017

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda